New Antidiabetic Agents Research from Chiang Mai University Outlined (Melatonin and Metformin Mitigate Doxorubicin-Induced Alveolar Bone Toxicity).

A recent study conducted by researchers at Chiang Mai University in Thailand explored the effects of doxorubicin, a chemotherapy drug, on alveolar bone homeostasis. The study also investigated the potential benefits of melatonin and metformin in mitigating the toxic effects of doxorubicin on the alveolar bone. The researchers found that doxorubicin treatment resulted in increased oxidative stress, inflammation, bone reabsorption, and impaired microarchitecture and periodontal condition of the alveolar bone. However, cotreatment with melatonin or metformin showed some improvement in these parameters, with melatonin being more effective in reducing oxidative stress, bone resorption, and improving microarchitecture and periodontal condition. These findings suggest that antioxidants, particularly melatonin, may have the potential to alleviate doxorubicin-induced alveolar bone toxicity. [Extracted from the article]